Literature DB >> 26567562

The epithelial-mesenchymal transition in cancer: a potential critical topic for translational proteomic research.

Patrizia Bottoni1, Maria Antonietta Isgrò2, Roberto Scatena1.   

Abstract

The epithelial-mesenchymal transition (EMT) is a morphogenetic process that results in a loss of epithelial characteristics and the acquisition of a mesenchymal phenotype. First described in embryogenesis, the EMT has been recently implicated in carcinogenesis and tumor progression. In addition, recent evidence has shown that stem-like cancer cells present the hallmarks of the EMT. Some of the molecular mechanisms related to the interrelationships between cancer pathophysiology and the EMT are well-defined. Nevertheless, the precise molecular mechanism by which epithelial cancer cells acquire the mesenchymal phenotype remains largely unknown. This review focuses on various proteomic strategies with the goal of better understanding the physiological and pathological mechanisms of the EMT process.

Entities:  

Keywords:  Cancer stem cells; circulating tumor cells; epithelial-mesenchymal transition; migrating cancer stem cells; oncoproteomics

Mesh:

Substances:

Year:  2015        PMID: 26567562     DOI: 10.1586/14789450.2016.1112742

Source DB:  PubMed          Journal:  Expert Rev Proteomics        ISSN: 1478-9450            Impact factor:   3.940


  8 in total

1.  Characterization of the molecular changes associated with the overexpression of a novel epithelial cadherin splice variant mRNA in a breast cancer model using proteomics and bioinformatics approaches: identification of changes in cell metabolism and an increased expression of lactate dehydrogenase B.

Authors:  Marina Rosso; Lara Lapyckyj; María José Besso; Marta Monge; Jaume Reventós; Francesc Canals; Jorge Oswaldo Quevedo Cuenca; María Laura Matos; Mónica Hebe Vazquez-Levin
Journal:  Cancer Metab       Date:  2019-05-09

2.  The metastasis suppressor RARRES3 as an endogenous inhibitor of the immunoproteasome expression in breast cancer cells.

Authors:  Alison M Anderson; Murugan Kalimutho; Sarah Harten; Devathri M Nanayakkara; Kum Kum Khanna; Mark A Ragan
Journal:  Sci Rep       Date:  2017-01-04       Impact factor: 4.379

3.  Notch3 Transactivates Glycogen Synthase Kinase-3-Beta and Inhibits Epithelial-to-Mesenchymal Transition in Breast Cancer Cells.

Authors:  Weiling Chen; Yongqu Zhang; Ronghui Li; Wenhe Huang; Xiaolong Wei; Yuanke Liang; Yunzhu Zeng; Min Chen; Lixin Zhang; Wenliang Gao; Yuanyuan Zhu; Yaochen Li; Guojun Zhang
Journal:  Cells       Date:  2022-09-14       Impact factor: 7.666

4.  Long non-coding RNA TUSC7 acts a molecular sponge for miR-10a and suppresses EMT in hepatocellular carcinoma.

Authors:  Yufeng Wang; Zhikui Liu; Bowen Yao; Changwei Dou; Meng Xu; Yumo Xue; Linglong Ding; Yuli Jia; Hongyong Zhang; Qing Li; Kangsheng Tu; Yang Jiao; Qingguang Liu; Cheng Guo
Journal:  Tumour Biol       Date:  2016-03-22

5.  LncRNA HULC enhances epithelial-mesenchymal transition to promote tumorigenesis and metastasis of hepatocellular carcinoma via the miR-200a-3p/ZEB1 signaling pathway.

Authors:  Shi-Peng Li; Hai-Xu Xu; Yao Yu; Jin-Dan He; Zhen Wang; Yan-Jie Xu; Chang-Ying Wang; Hai-Ming Zhang; Rong-Xin Zhang; Jian-Jun Zhang; Zhi Yao; Zhong-Yang Shen
Journal:  Oncotarget       Date:  2016-07-05

Review 6.  Palmitoylation: a protein S-acylation with implications for breast cancer.

Authors:  Alison M Anderson; Mark A Ragan
Journal:  NPJ Breast Cancer       Date:  2016-10-19

7.  Combined treatment with N-acetylcysteine and gefitinib overcomes drug resistance to gefitinib in NSCLC cell line.

Authors:  Jun Li; Xiao-Hui Wang; Jing Hu; Meng Shi; Lu Zhang; Hong Chen
Journal:  Cancer Med       Date:  2019-12-31       Impact factor: 4.452

Review 8.  Proteomic Technology "Lens" for Epithelial-Mesenchymal Transition Process Identification in Oncology.

Authors:  Monica Neagu; Carolina Constantin; Marinela Bostan; Constantin Caruntu; Simona Rebeca Ignat; Sorina Dinescu; Marieta Costache
Journal:  Anal Cell Pathol (Amst)       Date:  2019-10-29       Impact factor: 2.916

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.